Biocon LimitedNSE: BIOCON

Press Release Mar 07 2025

· Issued by Biocon Limited

Filed with NSE ·

On 6ix: 6ix.com/news/press-release-mar-07-2025-7

Biocon Limited has informed the Exchange regarding a press release dated March 07, 2025, titled "Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis".

View Attachment

6ix hasn’t read this filing yet.

Biocon Limited on 6ix

Earlier from Biocon

Later from Biocon

All Biocon news releases